jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Urinary Bladder - Medium Biopsy 1-3 cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Biopsy of bladder lesion.

₹370₹529

30% OFF

Urinary Bladder - Medium Biopsy 1-3 cm

  • Why is it done?
    • Tissue diagnosis of bladder lesions: To obtain cellular and histological samples from suspicious bladder lesions identified during cystoscopy for definitive diagnosis
    • Detection of malignancy: To identify and classify bladder cancer (urothelial carcinoma, squamous cell carcinoma, or adenocarcinoma) and determine tumor grade and stage
    • Evaluation of hematuria: Investigation of gross or persistent microscopic hematuria (blood in urine) of unknown etiology
    • Assessment of abnormal cystoscopic findings: Evaluation of visible mucosal abnormalities, masses, nodules, ulcerations, or areas of erythema identified during endoscopic examination
    • Monitoring for recurrence: Surveillance biopsies in patients with history of bladder cancer to detect early recurrence or field changes
    • Diagnosis of inflammatory/infectious conditions: To identify conditions such as cystitis, interstitial cystitis, or chronic inflammatory changes in the bladder mucosa
  • Normal Range
    • Normal/Expected Findings: Benign urothelial epithelium without malignancy, normal mucosa without inflammation, negative for dysplasia, carcinoma in situ (CIS), or malignant cells
    • Tissue characteristics: Well-preserved normal urothelial architecture with intact basement membrane, absence of atypia or increased mitotic activity
    • Specimen quality: Adequate tissue sample (1-3 cm) for histopathological evaluation, proper fixation and processing, sufficient cellularity for interpretation
    • Abnormal findings interpretation: Positive results indicate presence of dysplasia, carcinoma in situ, invasive carcinoma, or other significant pathology requiring clinical correlation and further management
  • Interpretation
    • Benign/Normal Result: No malignancy detected; normal urothelial lining with intact architecture. May indicate benign etiology of symptoms such as benign hematuria, infection, or inflammatory changes. Follow-up depends on clinical presentation.
    • Low-Grade Dysplasia (LGD): Abnormal cell growth with intact basement membrane; increased nuclear-to-cytoplasmic ratio but lower mitotic activity. Risk of progression to higher-grade lesions; warrants close follow-up with repeat cystoscopy and biopsies.
    • High-Grade Dysplasia (HGD) or Carcinoma In Situ (CIS): Significant cellular atypia with high mitotic activity but confined to mucosa (no basement membrane invasion). Significant risk of progression to invasive carcinoma; requires aggressive treatment including possible intravesical therapy or cystectomy.
    • Non-Muscle Invasive Cancer (NMIC): Ta (confined to mucosa), T1 (invades lamina propria), or TIS (carcinoma in situ). Staging and grading determine prognosis and treatment options (TURBT, chemotherapy, immunotherapy).
    • Muscle-Invasive Cancer (MIBC): T2 or higher; demonstrates invasion into muscularis propria or deeper tissues. More aggressive disease requiring radical cystoprostatectomy or multimodal therapy (chemotherapy, radiation); poor prognosis without definitive treatment.
    • Histological Variants: Special subtypes (squamous cell carcinoma, adenocarcinoma, small cell carcinoma) may be identified with specific treatment and prognostic implications distinct from conventional urothelial carcinoma.
    • Factors affecting interpretation: Biopsy site and depth of sampling, concurrent inflammation or infection, prior radiation or chemotherapy effects, immunosuppression status, specimen adequacy and orientation
  • Associated Organs
    • Primary organ: Urinary bladder (hollow muscular organ responsible for urine storage and elimination)
    • Related organ systems: Urinary system (kidneys, ureters, urethra), lymphatic system (pelvic and regional lymph nodes), adjacent pelvic organs (prostate, seminal vesicles in males; uterus, ovaries in females)
    • Conditions diagnosed: Bladder cancer (urothelial carcinoma ~90%, squamous cell carcinoma ~3-5%, adenocarcinoma ~1-2%), interstitial cystitis, radiation cystitis, infectious cystitis, chronic cystitis, bladder polyps, endometriosis of bladder
    • Associated systemic conditions: Schistosomiasis, chronic urinary retention, neurogenic bladder, spinal cord injury, chronic smoking, occupational chemical exposure, family history of bladder cancer
    • Potential complications from abnormal results: Local extension to adjacent tissues, regional lymph node involvement, distant metastatic disease (bone, liver, lungs, brain), urinary obstruction, sepsis from infection, loss of bladder function requiring urinary diversion
  • Follow-up Tests
    • Staging and imaging studies: CT chest/abdomen/pelvis or MRI pelvis to assess local extension and regional lymph node involvement; bone scan or PET-CT for suspected metastatic disease
    • Upper urinary tract imaging: CT urography or retrograde pyelography to evaluate upper urinary tract for synchronous lesions or urothelial cancer
    • Surveillance cystoscopy: Recommended every 3-6 months for first 2 years after NMIC treatment, then annually for up to 5 years; more frequent for high-grade disease or CIS
    • Urine cytology: Serial urine cytology surveillance for detection of recurrent or high-grade disease; particularly sensitive for high-grade lesions and CIS
    • Immunohistochemical studies: May include p53, Ki-67, CK20, GATA-3, or other markers to aid in diagnosis and prognostication; useful for confirming CIS or high-grade dysplasia
    • Molecular studies: Gene mutation analysis (FGFR3, TP53, PTEN) or microsatellite instability testing may be performed for prognostication and targeted therapy selection
    • Repeat biopsies: Required if initial biopsy inadequate, margins not assessable, or persistent symptoms; consider rebiopsy at 4-6 weeks for HGD/CIS confirmation
    • Laboratory tests: Renal function (creatinine, BUN), urinalysis, baseline serum electrolytes before intravesical therapy; tumor markers if indicated
    • Treatment planning studies: For muscle-invasive disease, comprehensive staging with multidisciplinary team consultation; radiation therapy simulation or surgical planning as appropriate
  • Fasting Required?
    • Fasting requirement: No, fasting is not required for urinary bladder biopsy
    • Anesthesia considerations: If general or spinal anesthesia is planned, fasting may be required (typically NPO after midnight); local or regional anesthesia does not require fasting
    • Medications to continue: Continue regular medications unless specifically instructed otherwise by urologist; continue essential cardiac, pulmonary, or neurological medications
    • Medications to avoid/modify: Discontinue anticoagulants (warfarin) 3-5 days prior; hold antiplatelet agents (aspirin, clopidogrel) 5-7 days before if possible (coordinate with cardiologist); hold NSAIDs for 2-3 days
    • Pre-procedure preparation: Void bladder completely before procedure; mild bowel prep may be requested; arrive with empty stomach if conscious sedation planned
    • Infection prophylaxis: Prophylactic antibiotics typically given before or immediately after procedure (fluoroquinolone, first-generation cephalosporin, or trimethoprim-sulfamethoxazole) to prevent urinary tract infection
    • Post-procedure instructions: Resume normal diet and medications after procedure; increase fluid intake to promote urine flow; expect dysuria, frequency, and mild hematuria for 1-2 days; void frequently to prevent clot retention

How our test process works!

customers
customers